首页> 外文期刊>生物医学研究杂志(英文版) >Pathogenesis of RON receptor tyrosine kinase in cancer cells:activation mechanism, functional crosstalk, and signaling addiction
【24h】

Pathogenesis of RON receptor tyrosine kinase in cancer cells:activation mechanism, functional crosstalk, and signaling addiction

机译:癌细胞中RON受体酪氨酸激酶的发病机制:激活机制,功能性串扰和信号成瘾

获取原文
获取原文并翻译 | 示例
       

摘要

The RON receptor tyrosine kinase,a member of the MET proto-oncogene family,is a pathogenic factor implicated in tumor malignancy.Specifically,aberrations in RON signaling result in increased cancer cell growth,survival,invasion,angiogenesis,and drug resistance.Biochemical events such as ligand binding,receptor overexpression,generation of structure-defected variants,and point mutations in the kinase domain contribute to RON signaling activation.Recently,functional crosstalk between RON and signaling proteins such as MET and EFGR has emerged as an additional mechanism for RON activation,which is critical for tumorigenic development.The RON signaling crosstalk acts either as a regulatory feedback loop that strengthens or enhances tumorigenic phenotype of cancer cells or serves as a signaling compensatory pathway providing a growth/survival advantage for cancer cells to escape targeted therapy.Moreover,viral oncoproteins derived from Friend leukemia or Epstein-Barr viruses interact with RON to drive viral oncogenesis.In cancer cells,RON signaling is integrated into cellular signaling network essential for cancer cell growth and survival.These activities provide the molecular basis of targeting RON for cancer treatment.In this review,we will discuss recent data that uncover the mechanisms of RON activation in cancer cells,review evidence of RON signaling crosstalk relevant to cancer malignancy,and emphasize the significance of the RON signaling addiction by cancer cells for tumor therapy.Understanding aberrant RON signaling will not only provide insight into the mechanisms of tumor pathogenesis,but also lead to the development of novel strategies for molecularly targeted cancer treatment.

著录项

  • 来源
    《生物医学研究杂志(英文版)》 |2013年第5期|345-356|共12页
  • 作者单位

    Cancer Biology Research Center,School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79119, USA;

    Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79119, USA;

    Cancer Biology Research Center,School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79119, USA;

    Department of Pharmaceutical Sciences,School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79119, USA;

    Department of Neurosurgery,First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;

    Viral Oncogenesis Section in State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:48:01
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号